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Summary The effect of 45min systemic heating at 41°C on plasma and RIF-1 tumour pharmacokinetics of
intraperitoneally administered melphalan (MEL) was studied in C3H mice. This heat dose causes greater
potentiation of MEL in tumour than in marrow cells, resulting in a therapeutic gain for the combined therapy
(Honess & Bleehen, 1985). MEL (7.5mgkg-1) was administered at the start of heating and concentrations
assayed from 20-90min by high-performance liquid chromatography (HPLC). With or without heat peak
concentrations were achieved by 20min and were 3 to 4pgml-1 in plasma and 1-3 gg-1 in tumour. Higher
MEL concentrations in both plasma and tumour were found in heated animals at times after 20min from
injection, but the effect was greater in plasma (2.5-4 fold) than in tumour (1.5-2 fold) where differences
were not always significant. At 40min after a dose of 7.5 mgkg 1, plasma and tumour concentrations in heated
animals were equivalent to those after 12.5mgkg-1 and 8.5mgkg-1, respectively, without heating.
Tumour/plasma ratios were usually lower in heated than in unheated animals where they often exceeded
100%. The apparent plasma elimination half-life (ti) was 17.5-25min in unheated and 24 44min in heated
animals. The area under the curve (AUC) was increased by a factor of 1.2-1.5 in heated animals, at least
partly due to a decrease in volume of distribution. The heat induced increase in MEL exposure may be
involved in the enhanced response to the drug, but does not appear to explain the therapeutic gain compaired
to MEL alone.
We have previously shown that potentiation of
melphalan (MEL) by 45min whole body heating at
41°C is greater in two tumours (RIF-1 and KHT)
than in normal marrow stem cells (CFUs) in C3H
mice (Honess & Bleehen, 1985). This results in a
therapeutic gain for the combination of whole body
heat with MEL. In contrast, under the same
conditions, no gain was found for the combination
with 3 other alkylating agents, (chlorambucil, cis-
platinum and cyclophosphamide), or the nitro-
soureas BCNU and CCNU (Honess & Bleehen,
1982, 1985). One of the possible mechanisms may
be alteration of drug pharmacokinetics by heat, a
topic on which few studies have been carried out
(Mimnaugh et al., 1978; Honess et al., 1980; Magin
et al., 1980). We have therefore studied the effect of
systemic heat at 41°C on the pharmacokinetrics of
MEL in plasma and in the RIF-1 tumour in order to
investigate whether any heat induced changes in
pharmacokinetics would account for the greater
heat potentiation in tumour. We have used a
paired-ion reversed-phase high-performance liquid
chromatography (HPLC) technique to assay MEL in
plasma and tumour in unheated and heated mice.
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Materials and methods
Mice
Female C3H/He mice were obtained from Olac
(Southern) Ltd, Bicester, UK. Female C3H/Km
mice were bred in this unit. Mice were treated at
20-30g weight.
Tumour
The RIF-1 tumour described by Twentyman et al.
(1980) was grown i.m. in the left hind leg, initiated
by an inoculum of 105 cells from culture. Animals
were treated when tumours reached mean leg
diameters of 9-11 mm, usually on Day 12 or 13
after inoculation. These tumours were slightly
larger than those used in the work in which heat
potentiation of mel was demonstrated (8-9.5mm
diameter, Honess & Bleehen, 1985). This was in
order to provide sufficient tumour for MEL assay.
All experiments reported in this paper were carried
out on tumour-bearing animals.
Hyperthermia
The method of inducing systemic hyperthermia by
enclosing animals in an incubator has been
previously described (Honess and Bleehen 1982).
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Rectal temperatures reached 41°+0.2°C within 5 to
10min of the start of heating. Central tumour
temperatures were within 0.2°C of rectal
temperature. A standard heat treatment of45min at
41°C was used, entailing a total of 50min in the in-
cubator. Thus for time points up to 45min, mice were
heated for the entire time of exposure to MEL,
whereas for later time points, mice were removed
from the incubator after the standard treatment
and kept at room temperature. Drug was always
given immediately before the start of heat.
Drug
MEL was kindly supplied by Dr Derry Wilman of
the Institute of Cancer Research, Sutton, UK. The
drug was dissolved in acid ethanol (5% conc. HCI
in 95% ethanol), diluted 1 in 10 with propylene
glycol-K2HPO4 buffer to bring the pH to 7.4, and
finally diluted 1:10 with cold Hanks' balanced salt
solution for injection. The final concentration of
ethanol was thus only 1%. It was made up
immediately before use, put on ice and injected
within 5min in a volume of l0mlkg-1. A dose of
7.5mgkg-1 was chosen for the majority of the
studies because it is the lowest dose in unheated
animals for which a therapeutic gain was found for
the RIF-I tumour and is a dose at which it is
possible to measure the tumour response in both
unheated and heated animals by growth delay
(Honess & Bleehen, 1985).
Measurement ofMEL concentrations
At the time of sacrifice mice were anaesthetised
with ether and bled by cardiac puncture using
heparinised syringes. Blood was put on ice and
plasmas were prepared as soon as possible (within
1 h) and frozen. Tumours were excised as rapidly as
possible and snap frozen immediately at -70°C.
They were stored at -20°C, then quickly thawed
and homogenised with 2 vol of cold water before
assay.
MEL was assayed by a paired-ion reversed phase
high-performance liquid chromatography technique
similar to that of Hinchliffe et al. (1983). Full
details will be given elsewhere (Lee & Workman, in
preparation). Briefly, samples were deproteinized
with 4 vol acetonitrile containing 1% v/v HCI. The
supernatant was removed and taken to dryness and
redissolved in running buffer. The column used was
a p Bondapak C18 Radial-Pak cartridge (8mm i.d.;
10Hm particle size; Waters Associates) and the
running buffer was 35% acetonitrile/water
containing 5mM pentane sulphonic acid and
10mM dibutylamine, adjusted to pH 3 with HCI.
The flow rate was 4mlmin-1 and absorbance was
monitored at 254mM. Concentrations were
obtained from peak heights with reference to linear
calibration curves.
Measurement ofMEL hydrolysis in vitro
Rates of MEL hydrolysis were measured in 0.2M
phosphate buffer pH 7.4 or in 1:1 buffer:plasma at
37°C and 41°C. MEL was spiked at 10igml-1 into
thermally equilibrated solutions kept in circulating
water baths at 37°C+0.1°C and 41°+0.1°C (Grant
Ltd., UK). Samples were taken for HPLC assay at
intervals up to 6h. The pH was checked at the end
of the experiments and confirmed still to be 7.4.
Estimation ofpharmacokinetic parameters
Post-peak plasma concentrations declined approxi-
mately exponentially. Plots of log plasma drug
concentration against time were fitted by a least
squares linear regression analysis, which yielded
plasma elimination half lives (ti) with confidence
limits. In vitro hydrolysis was also exponential and
the same method was used to calculate in vitro t2
values.
The area under the concentration x time curve
(AUC) was estimated using a trapezoidal rule
modification of Simpson's rule, taking the
geometric mean of measured drug concentrations at
each time point.
Analysis of the significance of differences
between MEL concentrations in heated and
unheated animals was carried out using the
Wilcoxon Mann-Whitney test. Differences in
elimination half-lives were compared using students
t distribution.
Results
Preliminary experiments with 7.5mgkg1 MEL
given intraperitoneally at the start of heating
showed a broad peak of MEL concentration from
10-20min after injection, which was unchanged by
heat. However at times after 20min higher
concentrations were seen in both plasma and
tumour of heated animals. In 4 subsequent
experiments, with larger numbers of anumals per
group (4 and 5), MEL concentrations were
measured only at 20, 40, 60 and 90min after drug
administration. At later times the concentrations of
drug fell very close to or below the limit of
detection (- 0.01 Igml -1).
Results for 2 experiments with i.p. administered
MEL are shown in Figure 1 and they illustrate the
greatest and smallest effects of heat observed in this
series of 4 experiments. Peak plasma concentrations
of 3-4jugml-1 were found at 20min, and no
difference was seen in heated animals. In
Experiment A plasma concentrations (panel a) wereHEAT AND MELPHALAN PHARMACOKINETICS 79
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Figure 1 Effect of heat (45min at 41°C) on the
plasma and tumour pharmacokinetics of 7.5 mgkg-I
melphalan given i.p. at the start of heating. Closed
symbols indicate unheated animals, open symbols
heated ones. Each point represents one animal. Panels
(a) and (b) show data for Expt A, and panels (c) and
(d) show data for Expt B. Panels (a) and (c) show
plasma data, panels (b) and (d) show the
corresponding tumour data. Lines are best fit by eye.
higher (P_0.025) in heated animals at 40min by a
factor of up to 4 and remained about 3 times
higher (P_0.005) for the rest of the measured time
course. In Experiment B (panel c) complete
separation between the heated an unheated groups
was seen only at 60min (PO0.005), although it is
clear that plasma MEL concentrations were
generally higher in the heated animals by about a
factor of 2 (P_0.005 at 40min, P<0.05 at 90min).
The MEL concentrations in the tumour (Figure 1,
panels b and d) tend to follow those in the plasma;
peak concentrations from 1 to 3 ugml-1 were
found at 20min. In Experiment A which showed
the larger increase in plasma concentrations in
heated animals, the clear difference between heated
and unheated tumours seen at 40 and 60min
(P<0.001, panel b) is less obvious at 90min
(P<0.05), and MEL concentrations are only 1.5 to
2 times higher in heated tumours. In Experiment B,
with a smaller increase in plasma concentrations in
heated animals, tumour concentrations are lower
than in Experiment A, and there is no significant
difference between concentrations in heated and
unheated tumours. Nevertheless median values for
heated tumours are consistently 1.5-2 times higher
than for unheated tumours from 20 to 60min, as in
Experiment A.
The data in Figure 1 therefore indicate that
systemic heat at 41°C causes higher plasma and
tumour MEL concentrations than are found in
unheated animals, but the effect is greater in
plasma than in tumour.
Tumour/plasma ratios for both experiments
shown in Figure 1 are presented in Table I. The
main feature of these data, confirmed in other
experiments, is that tumour/plasma ratios are lower
in heated animals. With the exception of the 60min
for Experiment B, tumour/plasma ratios measured
from 40 to 90min were 1.5 to 2 times higher in
unheated mice. Tumour/plasma ratios greater than
100% were found in Experiment A and in other
experiments (not shown).
It seemed possible that the effects shown in
Figure 1 might be due to the effect of heat on MEL
uptake from the peritoneum. We therefore repeated
the experiment giving MEL i.v. (Experiment C) and
the results for plasma are shown in Figure 2.
Plasma MEL concentrations were again higher in
heated than in unheated animals by a factor of 1.5-
2, and the results, show the same trend as those
shown in Figure 1. This indicates that the increased
MEL concentrations in heated animals cannot be
attributed to the effect of heat on uptake from
the peritoneum.
Table I Medians and ranges of tumour/plasma ratios in
unheated and heated animals following 7.5mgkg-1 MEL
i.p. immediately before the start ofheat (n=4 or 5)
Tumour/plasma ratio %
Expt A Expt B
Time after
MEL (min) Unheated Heated Unheated Heated
20 78 68 31 53
(44-121) (62-128) (25-47) (45-61)
40 154 104 62 36
(129-176) (92-116) (32-82) (28-91)
60 143 95 40 38
(101-170) (62-131) (10-58) (21-60)
90 100 50 77 40
(56-113) (32-59) (33-96) (22-55)
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Figure 2 Effect of heat (45min at 41°C) on the
plasma pharnacokinetics of 7.5 mgkg-1 melphalan
given i.v. at the start of heating. Closed symbols
represent unheated animals, open symbols represent
heated animals. Lines are best fit by eye.
The apparent plasma t' values for MEL in
heated and unheated animals for Experiments A, B
and C are presented in Table II. For the i.p. route
in unheated animals the t values of around 20min
are in good agreement with previously published
data (e.g. Hinchliffe et al., 1983) and are also very
similar to that for the i.v. route. In heated animals,
the calculated t2 values are significantly greater
than in unheated ones, but considering the shapes
of the elimination curves in Figure 1 (panels a and
Table II Apparent t' values (min) for MEL in unheated
and heated animals treated with 7.5mgkg MEL
Expt. Unheated Heated
A Expt.
(i.p.) 25 (20-32) 44 (34-60) 0.01 >P>0.001
B Expt. B
(i.p.) 17.5 (15-21) 24 (21-28) 0.01 >P>0.001
C Expt.
(i.v.) 19 (16-23) 18 (16-21) P>0.1
Values in brackets are 95% confidence limits
c) over only 4 time points, it is difficult to tell
whether there is a true lengthening of t2, or
alternatively whether the peak is being maintained
for rather longer. Any peak-broadening in the
plasma elimination curves did not appear
sufficiently marked to justify excluding data points
from the t' estimation. However, it is clear that the
lines joining median concentrations tended to be
parallel after 40min in all experiments. Moreover,
Table II shows that there was no change in
elimination t when MEL was given i.v. Taken
together these data suggest that the elevated plasma
and tumour concentrations probably result from a
heat-induced reduction in the volume of MEL
distribution. Heated animals suffered a weight loss
of 3, 5 and 7% at 20, 40 and 50min respectively
after the start of heating, which was rapidly
regained at normal temperature. This fluid loss
provides a plausible physiological explanation for
the reduced volume of MEL distribution.
It is clearly that the calculated plasma t' values
in heated animals are certainly no shorter than in
unheated animals. This is in contrast to in vitro
results for MEL hydrolysis. Data presented in
Table III show that in vitro hydrolysis proceeds
more slowly in plasma than in buffer, but that in
both environments the t' is shorter at 41°C by a
factor of 1.5 to 1.9. The values for MEL in buffer
at 37°C are in good agreement with the previously
published values of 58min and 60min obtained by
Table III t2 values for MEL in 0.2 M phosphate buffer pH 7.4 or 1:1 plasma:buffer
pH 7.4, measured at 37°C and 41°C in vitro.
42 37°C t4 41°C t4 37CtC/4 410C
(min) (min)
Expt. 1 Buffer 58 (54-63) 31 (29-33) 1.9
Plasma:buffer (1:1) 93 (83-106) 56 (49-66) 1.7
Expt. II Buffer 45 (40-52) 30 (27-34) 1.5
Plasma:buffer (1:1) 82 (73-94) 54 (40-58) 1.5
Values in brackets give q5% confidence limits
1 t) _
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estimation of residual alkylating activity using the
Epstein reagent or by titration of acid release
respectively (Workman et al., 1976).
A widely used index of drug exposure is the area
under the concentration x time curve (AUC). AUCs
have been calculated for plasma and tumour in
unheated and heated animals for experiments A, B
and C and are presented in Table IV. The change
in plasma AUC in heated animals is similar to the
change in tumour AUC, an increase by a factor of
1.2 to 1.5. The changes in AUC brought about by
heat depend on the precise shapes of the control
and heat curves in each particular case. In
Experiment A the increase in plasma AUC was
slightly greater than in tumour whereas in
Experiment B this small difference was reversed.
We conclude that in terms of AUC, heat causes no
consistent elevation in tumour compared to plasma
MEL exposure.
We wished to obtain some estimate of the MEL
dose in unheated animals which would give MEL
concentrations similar to those measured in heated
animals after 7.5mgkg-1 i.p. MEL (i.e. an iso-
effect dose), and thus to derive some alternative
measure of drug exposure modification by heat. On
the basis of Experiment A and another (not shown)
the 40min time point was selected as that when the
difference between plasma concentrations in heated
and unheated animals was greatest, and so in
experiments B and C we also measured MEL
concentrations for a range of drug doses in
unheated animals at 40min. The data are shown in
Figure 3. Lines of best fit have been drawn through
the data by eye for unheated animals, and hence
the iso-effect dose was estimated. For plasma in
Experiment B (i.p. administration, panel a) the
value is 12.5mgkg-1 and in Experiment C (i.v.
administration, panel c) the value is 13.0mgkg-1.
Table IV AUCO-gomin values for plasma and tumour in unheated and heated animals
Plasma Tumour
Unheated Heated Heatedl Unheated Heated Heatedl
Expt pgminml' pgminml - unheated ,ugming-' lgming-1 unheated
A
(i.p.) 110 169 1.5 112 157 1.3
B
(i p.) 122 152 1.2 48 69 1.5
C
(i.v.) 98 126 1.3 n.d. n.d. n.d.
n.d. not determined
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Figure 3 Geometric mean (n=5) plasma or tumour MEL concentrations at 40min after drug administration,
plotted against dose of drug given. Panel a shows plasma data for Expt B and panel b shows tumour data for
Expt B i.e. drug given i.p. Panel c shows plasma data for Expt C i.e. drug given i.v. Closed symbols indicate
data for unheated animals, open symbols for heated ones. Lines are best fit by eye.82 D.J. HONESS et al.
Thus the dose of MEL in unheated animals giving
the same mean plasma MEL concentrations at
40min as 7.5mgkg-1 in heated animals is larger
by a factor of - 1.7. However, for the tumour in
Experiment B, (panel b) the iso-effect dose is
8.5mgkg-, i.e. it is larger by a factor of only 1.1.
Discussion
There have been few studies to date on the effect of
heat, systemic or local, on drug pharmacokinetics.
Effects of local heating on pharmacokinetics in
mice under conditions of drug potentiation have
been reported by Honess et al. (1980) for MISO
and by Magin et al. (1980) for adriamycin. No
change in plasma clearance was found for either
drug, but evidence for increased drug metabolism in
heated tumours was found for adriamycin. The
effects of systemic heat at 42.3°C on adriamycin in
non-tumour bearing rabbits were reported by
Mimnaugh et al. (1978) and they found no
difference in plasma clearance. A number of groups
have measured drug concentrations in heated
tumours under conditions of potentiation and some
report increased uptake gr binding for cis-platinum
in mice (Alberts et al., 1980) and nitrogen mustard
in rabbits (Shingleton, 1962). Reduced
concentrations in mouse tumours have been
reported for misonidazole (Honess et al., 1980) and
cyclophosphamide and thiotepa (Longo et al.,
1983), also under conditions of drug potentiation.
Osieka et al. (1978) found no difference in methyl-
CCNU uptake in human colon xenografts in nude
mice.
In this study we have shown that systemic heat
at 41PC for 45min causes an increase in both
plasma and tumour concentrations of MEL, but
there is no evidence for a greater elevation in
tumour compared to plasma.
In general, tumour/plasma ratios were higher in
unheated animals than in heated ones. Nonetheless,
the time course of the rise and fall of
tumour/plasma ratios, peaking 40-60min after drug
administration, was similar in both heated and
unheated animals. Tumour/plasma ratios greater
than 100% were found in both heated and
unheated tumours; however, the highest values were
found in unheated tumours, as were a larger
proportion of high values. The accumulation of
MEL in murine leukaemia and human breast
tumour cells at normal temperature in vitro occurs
by means of two distinct amino acid carriers
(Vistica, 1979, Begleiter et al., 1979, 1980). Our
data can be interpreted as evidence for the
accumulation of MEL in a solid tumour, with the
additional suggestion that heat might impair the
functioning of the carrier systems. These
conclusions must necessarily be very tentative, since
we have only been able to measure average MEL
concentrations throughout the homogenised bulk of
the tumour. We have no information on
intracellular and extracellular concentrations of
MEL, which may differ substantially from one
another. Nonetheless, Begleiter et al. (1980) quote
cell:medium ratios of about 3.5 in MCF-7 breast
cancer cells in the presence of 10,pM 14C
melphalan, which is - 3pgml -1. We found
tumour/plasma ratios of up to 1.7 following peak
plasma concentrations of about 3pgml-1 (Figure 1,
Table I) and have also measured tumour/plasma
ratios well in excess of 2 following plasma
concentrations of about 6pgml 1 40min after a
dose of 20mgkg-1 MEL (data not shown). It
therefore seems possible that the accumulation
described in vitro may be attained in vivo.
The elimination t' of MEL was found to be no
shorter in heated than unheated animals. One might
have expected a shorter t' in heated animals, due
to the more rapid hydrolysis at 41°C which we
demonstrated in vitro (Table III). This disparity
might be because the hydrolysis contribution to
MEL elimination is relatively small, the t value for
MEL in 1:1 plasma:buffer in vitro being 80 or
90min at 37°C compared with an elimination t' in
the mouse of -20min. Alternatively it is possible
that heat in some way tends to lengthen the
elimination t of MEL, and that this is almost
compensated for by the increased rate of hydrolysis.
While this method of heating has been shown to
impair glomerular filtration. (M.I. Walton, personal
communication) it is unlikely that this would
greatly affect MEL clearance since it has been
reported that <2% of the injected dose was
excreted as MEL in mouse urine (Furner et al.,
1976). It has been shown that MEL does not
undergo important metabolism (Evans et al., 1982)
but that a major route of elimination of MEL in all
species examined is biliary excretion, (Furner &
Brown, 1980). We have no information -on the
effect of this method of systemic heating on biliary
excretion. Another important aspect of MEL
pharmacology is its binding to plasma proteins
(Ehrsson & Lonroth, 1982) which is 96% in mice
(F.Y.F. Lee, personal communication). It is not
possible to determine the effect of heat on protein
binding directly in vivo, and in the present work we
have determined total (bound plus free) con-
centrations. Since changes in protein binding could
affect the amount of MEL available for uptake into
cells, we are currently developing techniques to
study the effect of heat on protein binding in vitro.
The data for intravenously administered MEL
(Figure 2), also showing an increase in plasma
MEL concentration, indicated that the effect of
heat was not primarily on MEL uptake from theHEAT AND MELPHALAN PHARMACOKINETICS 83
peritoneum. The higher peak MEL concentration in
heated animals and unchanged t' were compatible
with a probable reduction of apparent volume of
distribution of the MEL in heated mice. This
would be consistent with the weight loss observed
during heating.
It is interesting that in two experiments (one
i.p., one i.v.) heating produced mean MEL
concentrations 40min after administration of
7.5mgkg-1 equivalent to those produced by
1.7 x that dose in unheated animals (Figure 3).
For bone marrow stem cells, 12.5mgkg-1 MEL in
unheated animals in equitoxic with 7.3mgkg-1 in
heated animals (Honess & Bleehen, 1985), also a
ratio of 1.7. If toxicity of MEL to bone marrow
stem cells is closely related to MEL plasma
concentration, as would seem possible, then the
effect of heat on MEL plasma concentration would
be sufficient to account for the heat potentiation of
MEL toxicity in CFUs. However, in RIF-I tumour
12.5mgkg-t MEL in unheated animals is equitoxic
with only 4.6mgkg-1 MEL in heated animals
(Honess & Bleehen, 1985), a ratio of 2.7. This
ratio is substantially larger than the ratio of doses
resulting in equal MEL plasma concentrations at
40min in unheated and heated animals (1.7, Figure
3, panel a). It is also very much greater than the
ratio of doses resulting in equal tumour
concentrations at 40min in unheated and heated
animals, which is 1.1 (Figure 3, panel b). Although
the small increase in MEL concentration in heated
tumours presumably contributes to the MEL
potentiation, it would appear to be only a small
component of the mechanism.
While it seems reasonable to compare changes in
tumour pharmacokinetics with changes in drug
toxicity in the tumour under the same conditions, it
is less satisfactory to compare changes in plasma
pharmacokinetics with changes in drug toxicity to
the marrow. Although the marrow is well perfused,
MEL access to cells requires carrier mediation, and
the behaviour of such carriers in CFUs, especially
under heated conditions, cannot be easily predicted.
It would therefore be preferable to monitor MEL
pharmacokinetics in the CFUs. However since the
CFUs comprise only 0.015% of the nucleated cells
of the bone marrow, and are only functionally
identificable, this is clearly impossible. Nonetheless
there is a good correlation between increase in
plasma MEL concentration and toxicity to CFUs.
The broad conclusion from this study is that
systemic heat at 41°C does increase plasma and
tumour MEL concentrations. However while
changes in plasma pharmacokinetics may account
for the increase in MEL toxicity to marrow, the
changes in tumour pharmacokinetics can only
contritute in a minor way to the greater heat
potentiation of MEL in tumour. These results
therefore do not explain the therapeutic gain found
for this combination of heat and MEL, and the
reason for this probably lies at the cellular
biochemical level.
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